IndraLab

Statements

Efsevin inhibits KCNH2. 2 / 2
| 2
reach
"To rule out the possibility that the observed prolongation of APD50 by efsevin in mice could be relevant for human therapy, we showed that efsevin does not influence action potential duration in human iPSC derived cardiomyocytes and does not block hERG activity."
29354781
reach
"To rule out that the observed prolongation of APD50 by efsevin in mice is not relevant for human therapy, we showed that efsevin does not influence action potential duration in human iPSC derived cardiomyocytes and does not block hERG."
29354781